Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Prins

Showing results (21-30 of 153) with videos related to

Pageof 16
Sort By:
Nature Reviews. Neurology|December 7, 2010
Alzheimer disease: MRI and CSF biomarkers in AD--accuracy and temporal changeNiels D Prins, John C van Swieten
Journal of Speech and Hearing Research|October 1, 1991
Syllabic stress and the occurrence of stutteringD Prins, C P Hubbard, M Krause
Journal of Speech and Hearing Research|September 1, 1980
Principal and differential effects of haoperidol and placebo treatments upon speech disfuluencies in stutterersD Prins, T Mandelkorn, F A Cerf
Alzheimer'S Research & Therapy|April 15, 2010
Can novel therapeutics halt the amyloid cascade?Niels D Prins, Pieter Jelle Visser, Philip Scheltens
Alzheimer'S Research & Therapy|September 23, 2011
Amyloid imaging in prodromal Alzheimer's diseaseRik Ossenkoppele, Bart Nm van Berckel, Niels D Prins
Alzheimer'S Research & Therapy|August 20, 2013
Amyloid imaging in clinical trialsRik Ossenkoppele, Niels D Prins, Bart Nm van Berckel
Journal of Neurology, Neurosurgery, and Psychiatry|August 18, 2004
Neuroanatomical localisation and clinical correlates of white matter lesions in the elderlyS Artero, H Tiemeier, N D Prins, et al.
Journal of the American Podiatric Medical Association|April 1, 1997
PMMA bead versus parenteral treatment of Staphylococcus aureus osteomyelitisG S Heard, L M Oloff, D A Wolfe, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 11, 2017
The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial designDaniela Bertens, Betty M Tijms, Lisa Vermunt, et al.
Alzheimer'S Research & Therapy|May 28, 2021
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's diseaseNiels D Prins, John E Harrison, Hui-May Chu, et al.
Pageof 16

Showing results (21-30 of 153) with videos related to

Sort By:
Pageof 16
Nature Reviews. Neurology|December 7, 2010
Alzheimer disease: MRI and CSF biomarkers in AD--accuracy and temporal changeNiels D Prins, John C van Swieten
Journal of Speech and Hearing Research|October 1, 1991
Syllabic stress and the occurrence of stutteringD Prins, C P Hubbard, M Krause
Journal of Speech and Hearing Research|September 1, 1980
Principal and differential effects of haoperidol and placebo treatments upon speech disfuluencies in stutterersD Prins, T Mandelkorn, F A Cerf
Alzheimer'S Research & Therapy|April 15, 2010
Can novel therapeutics halt the amyloid cascade?Niels D Prins, Pieter Jelle Visser, Philip Scheltens
Alzheimer'S Research & Therapy|September 23, 2011
Amyloid imaging in prodromal Alzheimer's diseaseRik Ossenkoppele, Bart Nm van Berckel, Niels D Prins
Alzheimer'S Research & Therapy|August 20, 2013
Amyloid imaging in clinical trialsRik Ossenkoppele, Niels D Prins, Bart Nm van Berckel
Journal of Neurology, Neurosurgery, and Psychiatry|August 18, 2004
Neuroanatomical localisation and clinical correlates of white matter lesions in the elderlyS Artero, H Tiemeier, N D Prins, et al.
Journal of the American Podiatric Medical Association|April 1, 1997
PMMA bead versus parenteral treatment of Staphylococcus aureus osteomyelitisG S Heard, L M Oloff, D A Wolfe, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 11, 2017
The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial designDaniela Bertens, Betty M Tijms, Lisa Vermunt, et al.
Alzheimer'S Research & Therapy|May 28, 2021
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's diseaseNiels D Prins, John E Harrison, Hui-May Chu, et al.
Pageof 16